Estados financieros detallados de OSR Holdings, Inc. (OSRH): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto -98.8%, margen operativo -9.3%, margen neto -8.4%.
Al precio actual de $0.12, OSRH presenta beneficios negativos (P/E no significativo) y un ROE del -16.47%. La capitalización bursátil es de $4M.
Cuenta de Resultados (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | $3.5M | $2.9M |
| Coste de Ventas | 0 | 0 | 0 | 0 | $2.7M | $2.3M |
| Beneficio Bruto | 0 | 0 | 0 | 0 | $811236 | $592905 |
| I+D | 0 | 0 | 0 | 0 | $161155 | $318446 |
| Generales y Administrativos | $23812 | $3308 | $35388 | $1.8M | $2.5M | $9.2M |
| Gastos Operativos | $23812 | $3308 | $35388 | $1.8M | $12.5M | $18.9M |
| Beneficio Operativo | -$23810 | -$3308 | -$35388 | -$1.8M | -$11.7M | -$18.3M |
| EBITDA | -$23810 | $233250 | $193097 | $3.7M | -$2.2M | -$19.1M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | $43011 | $506196 |
| Beneficio Antes de Impuestos | -$23812 | -$3308 | -$35388 | $944591 | -$11.9M | -$28.9M |
| Impuestos | 0 | 0 | 0 | $540811 | -$1.6M | -$1.8M |
| Beneficio Neto | -$23812 | -$3308 | -$35388 | $403780 | -$10.3M | -$18.0M |
| BPA | $-0.00 | $-0.00 | $-0.00 | $0.07 | $-0.54 | $-4.02 |
| BPA Diluido | $-0.00 | $-0.00 | $-0.00 | $0.07 | $-0.54 | $-4.02 |
| Acciones en Circulación (Diluidas) | $7.9M | $7.9M | $9.1M | $7.7M | $4.5M | $4.5M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | $627747 | $381269 | $484057 | $315669 |
| Beneficio Bruto | $261734 | $129703 | -$2.3M | $86605 |
| Beneficio Operativo | -$3.8M | -$6.4M | -$3.7M | -$3.0M |
| EBITDA | -$2.1M | -$5.1M | -$1.5M | $932104 |
| Beneficio Neto | -$2.1M | -$9.1M | -$2.9M | -$1.0M |
| BPA | $-0.71 | $-2.02 | $-0.77 | $-0.02 |
| BPA Diluido | $-0.71 | $-2.02 | $-0.77 | $-0.22 |
Balance (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $62653 | $4757 | $2238 | $15419 | $66135 | $1.7M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | 0 | $402 | 0 | 0 | $599065 |
| Inventario | 0 | 0 | $858 | 0 | 0 | $196432 |
| Activos Corrientes | $62653 | $4757 | $3511 | $22627 | $455398 | $2.8M |
| Inmovilizado Material | 0 | 0 | $295 | 0 | 0 | $252167 |
| Fondo de Comercio | 0 | 0 | $9642 | 0 | 0 | $24.9M |
| Activos Intangibles | 0 | 0 | $82335 | 0 | 0 | $142.5M |
| Activos Totales | $322749 | $705087 | $95982 | $36.6M | $2.3M | $171.2M |
| Cuentas por Pagar | 0 | $2847 | $3382 | $1.1M | $2.9M | $7.8M |
| Deuda a Corto | $300000 | $400000 | $904 | $72000 | $2.6M | $4.3M |
| Pasivos Corrientes | $321561 | $707207 | $4658 | $2.0M | $6.7M | $17.2M |
| Deuda a Largo | 0 | 0 | $101 | 0 | 0 | 0 |
| Pasivos Totales | $321561 | $707207 | $17216 | $40.5M | $8.8M | $44.2M |
| Reservas | -$23812 | -$27120 | $42 | -$3.9M | -$8.3M | -$37.2M |
| Patrimonio Neto | $1188 | -$2120 | $78766 | -$3.9M | -$6.5M | $77.6M |
| Deuda Total | $300000 | $400000 | $1240 | $72000 | $2.6M | $4.4M |
| Deuda Neta | $237347 | $395243 | -$998 | $56581 | $2.6M | $2.7M |
| Capital Circulante | -$258908 | -$702450 | -$1147 | -$2.0M | -$6.3M | -$14.3M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $2.2M | $1.7M | $1.6M | $1.5M |
| Activos Totales | $177.3M | $171.2M | $172.2M | $166.6M |
| Pasivos Totales | $43.1M | $44.2M | $44.8M | $41.7M |
| Patrimonio Neto | $81.9M | $77.6M | $103.9M | $104.3M |
| Deuda Total | $4.4M | $4.4M | $5.0M | $578187 |
Flujo de Caja (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$23812 | -$3308 | $846 | $403780 | -$2.0M | -$18.0M |
| Amortizaciones | 0 | 0 | $18 | 0 | 0 | $9.3M |
| Compensación en Acciones | 0 | 0 | 0 | 0 | 0 | 0 |
| Cambio en Capital Circulante | 0 | $2847 | $107 | $1.6M | $1.7M | $1.7M |
| Flujo de Caja Operativo | -$23812 | -$461 | -$410 | -$818766 | -$2.2M | -$4.3M |
| Inversiones (CapEx) | $2 | 0 | -$62 | 0 | 0 | -$176385 |
| Adquisiciones | 0 | 0 | $1415 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | -$36.0M | -$36.2M | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$23810 | -$461 | -$472 | -$818766 | -$2.2M | -$4.5M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$2.7M | -$1.1M | -$1.0M | -$2.4M |
| Inversiones (CapEx) | -$94190 | -$79514 | -$4 | $4 |
| Flujo de Caja Libre | -$2.8M | -$1.1M | -$1.0M | -$2.4M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | 0 | 0 | 0 | 0 |
Crecimiento y Márgenes (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Ingresos (anual) | | | | | | -17.7% |
| Crecimiento Beneficio Neto (anual) | | +86.1% | -969.8% | +1241.0% | -2658.1% | -74.4% |
| Crecimiento BPA (anual) | | +86.7% | -875.0% | +1941.0% | -852.1% | -644.4% |
| Cambio en Acciones (anual) | | +0.5% | +14.2% | -14.7% | -41.9% | +0.0% |
| Crecimiento FCF (anual) | | +98.1% | -2.4% | -173404.1% | -167.2% | -105.9% |
| Margen Bruto | | | | | 23.0% | 20.4% |
| Margen Operativo | | | | | -331.2% | -631.0% |
| Margen EBITDA | | | | | -60.9% | -656.5% |
| Margen Neto | | | | | -292.6% | -619.8% |
| Margen FCF | | | | | -62.0% | -155.0% |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | 57.3% | 13.1% | 6.3% |
Datos por Acción (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-0.00 | $-0.00 | $-0.00 | $-0.11 | $-0.49 | $-1.01 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $7.9M | $7.9M | $9.1M | $7.7M | $4.5M | $4.5M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -16.47% |
| Rentabilidad sobre capital invertido | -10.61% |
| Rentabilidad sobre activos | -9.08% |
| Margen bruto | -98.82% |
| Margen operativo | -933.75% |
| Margen neto | -836.91% |
Salud financiera
| Deuda / Patrimonio | 0.01 |
| Ratio corriente | 0.18 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -0.71 |
Ratios Clave (10 años)
| Año | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -3366.67 | -25250.00 | -2589.74 | 146.24 | -21.35 | -0.14 |
| P/VC | 67078.28 | -37779.72 | 1161.10 | -20.66 | -7.97 | 0.03 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 14.64 | 0.87 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 23.0% | 20.4% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | -331.2% | -631.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | -292.6% | -619.8% |